# AstraZeneca Plc Entered into an agreement with Covis Pharma B.V.

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-entered-into-an-agreement-with-covis-pharma-b-v/412760839
- Published: 2018-11-06T07:25:24+00:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
LONAZN) has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell
its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent
asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms
associated with rhinitis. The rights cover markets outside the US and the US royalties
for the medicines. Covis Pharma currently commercialises Alvesco, Omnaris and Zetonna
in the US and will become the owner of the medicines upon closing. The transaction
does not include the transfer of any AstraZeneca employees or facilities.

> **Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy,
> said:** “One of our strategic objectives is to divest parts of our portfolio, 
> allowing us to allocate resources to develop innovative new medicines to address
> unmet patient needs. Covis Pharma has strong capabilities in marketing medicines
> around the world, and our agreement with them means patients will continue to 
> benefit from Alvesco, Omnaris and Zetonna.”
> **Michael Porter, Chief Executive Officer, Covis Pharma, said:** “This is an exciting
> milestone for Covis Pharma and aligned with our strategy to build a global respiratory/
> allergy franchise. When we acquired the US rights for Alvesco, Omnaris and Zetonna
> in 2017, we recognised the importance of these medicines in the respiratory and
> allergy therapeutic area and we look forward to extending our reach to meet the
> needs of patients and physicians around the world.”

Alvesco is an inhaled anti-inflammatory maintenance therapy delivered by a metered-
dose inhaler to help control persistent asthma. Omnaris and Zetonna are nasal sprays
for the treatment of nasal symptoms associated with seasonal allergic and allergic/
non-allergic perennial rhinitis. The active ingredient in all three medicines is
ciclesonide, a synthetic corticosteroid that helps relieve inflammation.

**Financial Considerations**

Covis Pharma will pay AstraZeneca $350 million upon closing, in addition to conditional
sales-related payments of up to $21 million over four years from 2019. The agreement
is subject to customary closing conditions and is expected to complete by the end
of 2018. As AstraZeneca will not maintain a significant ongoing interest in the 
medicines following completion, the payments will be recognised as Other Operating
Income in the Company’s financial statements. Combined 2017 Product Sales of Alvesco,
Omnaris and Zetonna, recorded by AstraZeneca, were $106 million. The agreement does
not affect the Company’s financial guidance for 2018.

Share on:
